ECI2 and prostate carcinoma: Similarly, 2,4-dienoyl-CoA reductase (DECR1) and enoyl-CoA delta isomerase 2 (ECI2), auxiliary enzymes responsible for the degradation of unsaturated fatty acids, are also essential for prostate cancer growth and therapy resistance (84–86).